Mural Oncology Achieves Required Overall Survival Events in Trial, Extends Cash Runway

MT Newswires Live

01-10

Mural Oncology (MURA) said Thursday it achieved 75% of the required overall survival events for the planned interim analysis in its ARTISTRY-7 trial evaluating nemvaleukin with pembrolizumab for platinum-resistant ovarian cancer.

The company said it extended its cash runway projection into Q1 2026.

Mural also expanded its pipeline in Q4 2024 by nominating two new development candidates for its interleukin-18 and interleukin-12 programs, it added.

The company said it anticipates filing an Investigational New Drug application or Clinical Trial Application for a phase 1 trial of MURA-8518 in Q4 2025.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2502735350"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2502735350\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2502735350?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-10 06:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2502735350","market":"sg","top_or_hot":-1,"title":"Mural Oncology Achieves Required Overall Survival Events in Trial, Extends Cash Runway","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/MURA\">Mural Oncology</a> (MURA) said Thursday it achieved 75% of the required overall survival events for the planned interim analysis in its ARTISTRY-7 trial evaluating nemvaleukin with pembrolizumab for platinum-resistant ovarian cancer.</p><p>The company said it extended its cash runway projection into Q1 2026.</p><p>Mural also expanded its pipeline in Q4 2024 by nominating two new development candidates for its interleukin-18 and interleukin-12 programs, it added.</p><p>The company said it anticipates filing an Investigational New Drug application or Clinical Trial Application for a phase 1 trial of MURA-8518 in Q4 2025.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mural Oncology Achieves Required Overall Survival Events in Trial, Extends Cash Runway</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMural Oncology Achieves Required Overall Survival Events in Trial, Extends Cash Runway\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-01-10 06:42</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/MURA\">Mural Oncology</a> (MURA) said Thursday it achieved 75% of the required overall survival events for the planned interim analysis in its ARTISTRY-7 trial evaluating nemvaleukin with pembrolizumab for platinum-resistant ovarian cancer.</p><p>The company said it extended its cash runway projection into Q1 2026.</p><p>Mural also expanded its pipeline in Q4 2024 by nominating two new development candidates for its interleukin-18 and interleukin-12 programs, it added.</p><p>The company said it anticipates filing an Investigational New Drug application or Clinical Trial Application for a phase 1 trial of MURA-8518 in Q4 2025.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2502735350","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2502735350","pubTimestamp":1736462526,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Mural Oncology  said Thursday it achieved 75% of the required overall survival events for the planned interim analysis in its ARTISTRY-7 trial evaluating nemvaleukin with pembrolizumab for platinum-resistant ovarian cancer.The company said it extended its cash runway projection into Q1 2026.Mural also expanded its pipeline in Q4 2024 by nominating two new development candidates for its interleukin-18 and interleukin-12 programs, it added.The company said it anticipates filing an Investigational New Drug application or Clinical Trial Application for a phase 1 trial of MURA-8518 in Q4 2025.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","MURA":"Mural Oncology"},"translate_title":"Mural Oncology在试验中达到了所需的总生存事件，扩大了现金跑道","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MURA":1},"content_text":"Mural Oncology (MURA) said Thursday it achieved 75% of the required overall survival events for the planned interim analysis in its ARTISTRY-7 trial evaluating nemvaleukin with pembrolizumab for platinum-resistant ovarian cancer.The company said it extended its cash runway projection into Q1 2026.Mural also expanded its pipeline in Q4 2024 by nominating two new development candidates for its interleukin-18 and interleukin-12 programs, it added.The company said it anticipates filing an Investigational New Drug application or Clinical Trial Application for a phase 1 trial of MURA-8518 in Q4 2025.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1}}}